Search Results - "Schusterbauer, Claudia" :: K.UTB vyhledávací portál

Safety and activity of alisertib, an investigational aurora kinase A inhibitor, in patients with breast cancer, small-cell lung cancer, non-small-cell lung cancer, head and neck squamous-cell carcinoma, and gastro-oesophageal adenocarcinoma: a five-arm phase 2 study

by Melichar, Bohuslav, Prof, Adenis, Antoine, Prof, Lockhart, A Craig, MD, Bennouna, Jaafar, Prof, Dees, E Claire, Prof, Kayaleh, Omar, MD, Obermannova, Radka, MD, DeMichele, Angela, MD, Zatloukal, Petr, Prof, Zhang, Bin, DSc, Ullmann, Claudio Dansky, MD, Schusterbauer, Claudia, MD
Published in The lancet oncology (01.04.2015)

Get full text

Journal Article

Loading…

$Phase 2 results of lisocabtagene maraleucel in Japanese patients with relapsed/refractory aggressive B‐cell non‐Hodgkin lymphoma$

Phase 2 results of lisocabtagene maraleucel in Japanese patients with relapsed/refractory aggressive B‐cell non‐Hodgkin lymphoma

by Makita, Shinichi, Yamamoto, Go, Maruyama, Dai, Asano‐Mori, Yuki, Kaji, Daisuke, Ananthakrishnan, Revathi, Ogasawara, Ken, Stepan, Lara, Schusterbauer, Claudia, Rettby, Nils, Hasskarl, Jens, Izutsu, Koji
Published in Cancer medicine (Malden, MA) (01.12.2022)

Get full text

Journal Article

Loading…

OMNIA-1: A phase I/II study, an IL-2R-βγ targeted antibody-IL-2 fusion protein, as monotherapy or in combination with anti-PD-1 or anti-CTLA-4 antibodies, in patients with advanced melanoma

by Ascierto, Paolo Antonio, de Velasco, Guillermo, Eigentler, Thomas, Isambert, Nicolas, Mouton, Julie, Robert, Caroline, Schusterbauer, Claudia Michaela, Vijayakumar, Jayanthi
Published in Journal of clinical oncology (01.06.2023)

Get full text

Journal Article

Loading…

$Use of a real-world synthetic control arm for direct comparison of lisocabtagene maraleucel and conventional therapy in relapsed/refractory large B-cell lymphoma$

Use of a real-world synthetic control arm for direct comparison of lisocabtagene maraleucel and conventional therapy in relapsed/refractory large B-cell lymphoma

by Van Le, Hoa, Van Naarden Braun, Kim, Nowakowski, Grzegorz S., Sermer, David, Radford, John, Townsend, William, Ghesquieres, Herve, Menne, Tobias, Porpaczy, Edit, Fox, Christopher P., Schusterbauer, Claudia, Liu, Fei Fei, Yue, Lihua, De Benedetti, Marc, Hasskarl, Jens
Published in Leukemia & lymphoma (23.02.2023)

Get full text

Journal Article

Loading…

Abstract C2: Clinical safety, pharmacokinetics and early evidence of activity of the oral IAPs inhibitor Debio 1143 in combination with carboplatin and paclitaxel: a phase Ib study

by Ray-Coquard, Isabelle, Le Tourneau, Christophe, Isambert, Nicolas, Gomez-Roca, Carlos A., Cassier, Philippe, Sablin, Marie Paule, Gavillet, Bruno, Purcea, Daniela, Rouits, Elisabeth, Schusterbauer, Claudia, Zanna, Claudio, Fumoleau, Pierre, Delord, Jean-Pierre
Published in Molecular cancer therapeutics (01.12.2015)

Get full text

Journal Article

Loading…

Phase (Ph) I/II study of investigational Aurora A kinase (AAK) inhibitor MLN8237 (alisertib): Updated ph II results in patients (pts) with small cell lung cancer (SCLC), non-SCLC (NSCLC), breast cancer (BrC), head and neck squamous cell carcinoma (HNSCC), and gastroesophageal cancer (GE)

by Melichar, Bohuslav, Adenis, Antoine, Havel, Libor, Lockhart, Albert C., Bennouna, Jaafar, Schusterbauer, Claudia, Dansky Ullmann, Claudio, Zhang, Bin, Benaim, Ely, Dees, Elizabeth Claire
Published in Journal of clinical oncology (20.05.2013)

Get full text

Journal Article

Loading…

Phase I/II study of the investigational aurora A kinase (AAK) inhibitor MLN8237 (alisertib) in patients (pts) with non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), breast cancer (BrC), head/neck cancer (H&N), and gastroesophageal (GE) adenocarcinoma: Preliminary phase II results

by Lee, Peter, Alvarez, Ricardo H., Melichar, Bohuslav, Adenis, Antoine, Bennouna, Jaafar, Schusterbauer, Claudia, Zhang, Bin, Benaim, Ely, Rosen, Peter J.
Published in Journal of clinical oncology (20.05.2012)

Get full text

Journal Article